| NCT ID | NCT07477067 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Urbana-Champaign |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-02-09 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-02-09 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this randomized controlled trial, 30 older adults (aged\> 65 years; 15 with T2D, 15 controls) will participate in a 12-week progressive exercise training program. They will undergo pre- and post-testing that includes body composition measures; oral glucose tolerance testing; cardiovascular fitness and muscle performance testing; dietary protein efficiency assessed using the indicator amino acid oxidation (IAAO) method; and a gut microbiota trial. The dietary protein efficiency trial will include repeated ingestion of crystallized amino acids (drink) containing stable isotopes, urine samples, and breath samples. The gut microbiome trial will consist of a single ingestion of a Mediterranean-based modeled meal enriched with 13C-phenylalanine (in the drink) and repeated blood draws. Participants will also be asked to give a fecal sample after the gut microbiome trial.
Eligibility Criteria
Inclusion Criteria: * At least 65 years old * Body mass index: 25-40 kg/m\^2 * Female: Waist to hip ratio \>0.8 * Male: Waist to hip ratio \>1.0 * Free from structured exercise during the prior 6 months (mo) weight stable for the prior 6 months T2D group: -Diagnosed by a physician with elevated glycosylated hemoglobin (HbA1c) \>6.5% Control group: -Normoglycemic with HbA1c levels not exceeding 5.6% and fasting blood glucose levels below or equal to 99 mg/dL (5.5mmol) Exclusion Criteria: * Uncontrolled diabetes (evidence of HbA1c \> 10%, prescription of insulin) * Diagnoses of diabetic neuropathy or failing diabetic neuropathy screening * Statins * Peripheral edema Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation. * Untreated hypothyroidism, epilepsy, medications that affect vasoactivity, possibility of pregnancy, and any neurological, cardiovascular, or musculoskeletal disease that precludes exercise testing.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07477067 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07477067 currently recruiting?
Yes, NCT07477067 is actively recruiting participants. Contact the research team at naburd@illinois.edu for enrollment information.
Where is the NCT07477067 trial being conducted?
This trial is being conducted at Urbana, United States.
Who is sponsoring the NCT07477067 clinical trial?
NCT07477067 is sponsored by University of Illinois at Urbana-Champaign. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.